ESTRO 2024 - Abstract Book

S1057

Clinical - Gynaecology

ESTRO 2024

(CRT group); (4) incomplete surgical staging or remaining macroscopic LN followed by 45-50.4Gy CRT with or without LN boost (combined treatment group). Frequency analysis was performed for selected morbidity endpoints potentially associated with LN management. Maximum grade of gastrointestinal (GI = diarrhea, flatulence, bleeding, stricture, fistula, pain, constipation), genitourinary (GU = ureter stenosis and fistula), musculoskeletal (MSK = fibrosis, fracture, pain, soft-tissue oedema) and lymphatic (LYM = lymphoedema, lymphocele) morbidity during follow-up (FUP) was evaluated in relationship to the overall cohort and per nodal management strategy. Differences between groups (1+4 vs. 2+3; 2 vs. 3; 1 vs. 2) were compared by Chi-Square test.

Results:

In total, 164 patients were available for analysis. Median FUP was 40 months (12-88 IQR). Characteristics of the overall cohort and overall morbidity based on LN management strategy are shown in table 1. Overall crude incidence of mild-to-moderate G1-G2 morbidity was: 49 (29,9%), 6 (3,6%), 27 (16,5%) and 31 (18,9%) for GI, GU, MSK, and LYM respectively. Severe G3-G5 morbidity was observed in 7 (4,2%), 8 (4,9%), 2 (1,2%), and 2 (1,2%) for GI, GU, MSK and LYM respectively. Differences between the above-mentioned groups are shown in table 2.